API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for the treatment of IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2023
Details:
AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Data from the ongoing perioperative study found that treatment with vorasidenib 50mg and TIBSOVO 500mg resulted in mean percent reduction in 2-HG (95% CI) of 92.6% (76.1, 97.6) and 91.1% (72, 97) respectively, relative to untreated samples in patients with low-grade glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
In-line with Servier’s strategy, this acquisition will enable the Group to strengthen its product portfolio and drug development pipeline in oncology. Includes Agios’ marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: $2,000.0 million Upfront Cash: $1,800.0 million
Deal Type: Acquisition December 21, 2020
Details:
Vorasidenib demonstrated prolonged disease control and encouraging preliminary activity with median progression-free survival of 31.4 months.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Vorasidenib and ivosidenib clinical data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020